469 related articles for article (PubMed ID: 27197158)
21. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
22. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
23. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan.
Lamming DW; Mihaylova MM; Katajisto P; Baar EL; Yilmaz OH; Hutchins A; Gultekin Y; Gaither R; Sabatini DM
Aging Cell; 2014 Oct; 13(5):911-7. PubMed ID: 25059582
[TBL] [Abstract][Full Text] [Related]
24. mTOR complex 2 mediates Akt phosphorylation that requires PKCε in adult cardiac muscle cells.
Moschella PC; McKillop J; Pleasant DL; Harston RK; Balasubramanian S; Kuppuswamy D
Cell Signal; 2013 Sep; 25(9):1904-12. PubMed ID: 23673367
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
26. Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure.
Chen Z; Kang X; Wang L; Dong H; Wang C; Xiong Z; Zhao W; Jia C; Lin J; Zhang W; Yuan W; Zhong M; Du H; Bai X
J Biol Chem; 2015 Mar; 290(10):6387-96. PubMed ID: 25564616
[TBL] [Abstract][Full Text] [Related]
27. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
[TBL] [Abstract][Full Text] [Related]
28. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
[TBL] [Abstract][Full Text] [Related]
29. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
Koo J; Wu X; Mao Z; Khuri FR; Sun SY
J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
[TBL] [Abstract][Full Text] [Related]
30. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
31. Down regulation of Peroxiredoxin-3 in 3T3-L1 adipocytes leads to oxidation of Rictor in the mammalian-target of rapamycin complex 2 (mTORC2).
Olson DH; Burrill JS; Kuzmicic J; Hahn WS; Park JM; Kim DH; Bernlohr DA
Biochem Biophys Res Commun; 2017 Nov; 493(3):1311-1317. PubMed ID: 28986255
[TBL] [Abstract][Full Text] [Related]
32. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
[TBL] [Abstract][Full Text] [Related]
33. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.
Shu L; Houghton PJ
Mol Cell Biol; 2009 Sep; 29(17):4691-700. PubMed ID: 19564418
[TBL] [Abstract][Full Text] [Related]
34. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
35. Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis.
Li J; Ren J; Liu X; Jiang L; He W; Yuan W; Yang J; Dai C
Kidney Int; 2015 Sep; 88(3):515-27. PubMed ID: 25970154
[TBL] [Abstract][Full Text] [Related]
36. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
37. Hepatic FOXO1 Target Genes Are Co-regulated by Thyroid Hormone via RICTOR Protein Deacetylation and MTORC2-AKT Protein Inhibition.
Singh BK; Sinha RA; Zhou J; Tripathi M; Ohba K; Wang ME; Astapova I; Ghosh S; Hollenberg AN; Gauthier K; Yen PM
J Biol Chem; 2016 Jan; 291(1):198-214. PubMed ID: 26453307
[TBL] [Abstract][Full Text] [Related]
38. XPLN is an endogenous inhibitor of mTORC2.
Khanna N; Fang Y; Yoon MS; Chen J
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15979-84. PubMed ID: 24043828
[TBL] [Abstract][Full Text] [Related]
39. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.
Goncharov DA; Kudryashova TV; Ziai H; Ihida-Stansbury K; DeLisser H; Krymskaya VP; Tuder RM; Kawut SM; Goncharova EA
Circulation; 2014 Feb; 129(8):864-74. PubMed ID: 24270265
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
